Our Research Projects

ARCoV-005

A Global, Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older

Find More >>

Monovalen Fase-I

A Randomized, Double-Blind, and Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant mRNA Vaccines (ABO1009-DP and ABO-CoV.617.2) in Indonesian Subjects Aged 18 Years and Older Who Have Not Received SARS-CoV-2 Vaccines

Find More >>

Monovalent BA 4/5 Fase 1, 2/3

This study is a randomized, double-blind, and actively controlled clinical trial aimed at evaluating the efficacy, safety, tolerability, and immunogenicity of the modified mRNA vaccine (ABO1020) in healthy individuals aged 18 and above who have completed full COVID-19 vaccination. The study aims to ascertain and assess the efficacy produced by ABO1020 against confirmed cases of COVID-19 occurring from 14 days after the administration of the second dose, compared to placebo. This research is conducted in three countries: Indonesia, the Philippines, and the UAE.